8-K: Precigen Reports Strong Q2 2026 Results, PAPZIMEOS Drives Profitability

Precigen announced robust second quarter 2026 financial results, highlighted by significant revenue growth from PAPZIMEOS and a notable shift to profitability.

Summary

• Precigen reported strong financial results for the second quarter of 2026, with total revenues reaching $55.0 million, a substantial increase from $0.86 million in the prior year period.
• PAPZIMEOS, the company's therapy for recurrent respiratory papillomatosis (RRP), generated $53.1 million in net revenue during the quarter, more than doubling from the previous quarter.
• The company achieved net income of $20.1 million ($0.06 per basic share, $0.05 per diluted share) for Q2 2026, a significant turnaround from a net loss of $26.6 million in Q2 2025.
• For the first six months of 2026, total revenues were $78.2 million, with PAPZIMEOS contributing $74.7 million.
• The company expects to reach cash flow break-even by the end of 2026, supported by current cash reserves and PAPZIMEOS revenue.
• PAPZIMEOS has received FDA market exclusivity for seven years and has a permanent J-code (J3404) for reimbursement.
• Over 500 patients have enrolled in the PAPZIMEOS patient hub, indicating broad US adoption.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, driven by strong revenue growth and the achievement of profitability, largely due to the successful commercialization of PAPZIMEOS.

Positives

• PAPZIMEOS net revenue reached $53.1 million in Q2 2026, more than doubling from the prior quarter, demonstrating accelerating commercial momentum.
• The company achieved quarterly profitability with a net income of $20.1 million for Q2 2026.
• PAPZIMEOS revenue is propelling the company towards cash flow break-even by the end of 2026.
• PAPZIMEOS has secured seven-year market exclusivity from the FDA.
• A permanent J-code (J3404) has been assigned to PAPZIMEOS, facilitating reimbursement.
• PAPZIMEOS has broad payer coverage across approximately 315 million US lives.
• Over 500 patients have enrolled in the PAPZIMEOS patient hub, indicating strong adoption.
• An expert position paper recommended PAPZIMEOS as the first-line standard of care for adults with RRP.

Negatives

• Selling, general and administrative (SG&A) expenses increased by $6.1 million in Q2 2026 compared to the prior year, driven by commercialization activities.
• Total other expense, net was $2.6 million in Q2 2026, a significant change from other income of $5.1 million in Q2 2025, primarily due to the absence of a gain on warrant liabilities and increased interest expense.
• Cash, cash equivalents, and investments totaled $38.7 million as of June 30, 2026, which may require careful management to sustain operations until cash flow break-even.

Risks

• The company has no obligation to provide updates to forward-looking statements even if expectations change.
• Potential risks and uncertainties that could cause actual results to differ from forward-looking statements are detailed in the Company's most recent Annual Report on Form 10-K and subsequent SEC filings.
• The European Medicines Agency (EMA) is reviewing the Marketing Authorization Application (MAA) for PAPZIMEOS, and approval is not guaranteed.

Future Outlook

The company anticipates continued growth in PAPZIMEOS demand and expects to reach cash flow break-even by the end of 2026, supported by current cash and PAPZIMEOS revenue. A pipeline update for the AdenoVerse portfolio, including PRGN-2009, is expected by year-end 2026. The company also plans to expand PAPZIMEOS globally and into the pediatric population.

Management Comments

• "We delivered a historic second quarter, with the rapid adoption of PAPZIMEOS demonstrating the strength of our groundbreaking science and innovative commercial strategy," said Helen Sabzevari, PhD, President and CEO of Precigen.
• "This momentum provides a strong foundation for our next phase of growth as we work to expand PAPZIMEOS globally and into the pediatric population."
• "With growing commercial momentum, a validated platform, and multiple opportunities ahead, we believe Precigen is well positioned to deliver sustained value for patients across various indications, the broader healthcare community, and our shareholders."
• "We are thrilled to report that Precigen achieved profitability in the second quarter, marking a significant milestone for the company. Net income was driven by strong PAPZIMEOS revenue of $53.1 million."
• "As we progress through the third quarter of 2026, we are seeing continued growth in PAPZIMEOS demand," said Harry Thomasian Jr., Chief Financial Officer of Precigen.
• "Based upon our current revenue trajectory and present financial forecast, we continue to believe that our current cash position and anticipated cash to be received from PAPZIMEOS sales will fund operations through cash flow break-even by the end of 2026."

Industry Context

StockSavvy.ai notes that Precigen's strong performance with PAPZIMEOS aligns with the broader biopharmaceutical trend of focusing on precision medicines and targeted therapies for specific unmet medical needs. The rapid adoption and market exclusivity highlight the value of innovative treatments in niche indications.

Stakeholder Impact

• Shareholders: The achievement of profitability and strong revenue growth from PAPZIMEOS is expected to positively impact shareholder value.
• Patients: Continued expansion of PAPZIMEOS access and potential global reach will benefit patients suffering from RRP.
• Healthcare Providers: The permanent J-code and broad payer coverage simplify reimbursement and integration of PAPZIMEOS into clinical workflows.

Next Steps

• Expand PAPZIMEOS globally and into the pediatric population.
• Provide a pipeline update on the AdenoVerse portfolio, including PRGN-2009, by the end of 2026.
• Continue to convert demand into treated patients and expand access to PAPZIMEOS.
• The company's open-label study to evaluate redosing efficacy of zopapogene imadenovec in adults with RRP is currently enrolling.
• The European Medicines Agency (EMA) is reviewing the Marketing Authorization Application (MAA) for PAPZIMEOS.

Key Dates

Recommendation

The filing demonstrates a significant inflection point for Precigen, marked by the highly successful commercial launch of PAPZIMEOS, leading to substantial revenue growth and profitability. The company's clear path to cash flow break-even, coupled with strong market adoption, FDA exclusivity, and a promising pipeline, suggests significant upside potential. This performance indicates a strong buy recommendation for seasoned investors and institutions.

Keywords

PAPZIMEOS, RRP, Recurrent Respiratory Papillomatosis, HPV, Immunotherapy, Biopharmaceutical, Financial Results, Commercialization